✦ LIBER ✦

The statistical development of endpoints for Alzheimer's disease clinical trials

✍ Scribed by Raghavan, Nandini

Book ID: 123145922
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 51 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.04.330

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analytic methods for factors, dimensions

Analytic methods for factors, dimensions and endpoints in clinical trials for Alzheimer’s disease

✍ R. E. Tractenberg 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 89 KB

Alzheimer's disease: clinical trials and

Alzheimer's disease: clinical trials and drug development

✍ Francesca Mangialasche; Alina Solomon; Bengt Winblad; Patrizia Mecocci; Miia Kiv 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 230 KB

Alzheimer's disease: clinical trials and

Alzheimer's disease: clinical trials and drug development

✍ Francesca Mangialasche; Alina Solomon; Bengt Winblad; Patrizia Mecocci; Miia Kiv 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 230 KB

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These success

Endpoints for trials in Alzheimer's dise

Endpoints for trials in Alzheimer's disease: a European task force consensus

✍ Bruno Vellas; Sandrine Andrieu; Cristina Sampaio; Nicola Coley; Gordon Wilcock 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 133 KB

Clinical Trials of Intravenous Immunoglo

Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

✍ Relkin, Norman 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 270 KB

Endpoints in lung cancer trials: today’s

Endpoints in lung cancer trials: today’s challenges for clinical statistics

✍ Dipl.Math Lothar R Pilz… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 943 KB